Fleebs-Logo
Details werden geladen...

Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting...

ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients

Ähnliche Seiten

https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting/2349722

Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting | The Manila Times

https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting/2349722
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/remix-therapeutics-announces-positive-data-from-phase-12-aria-study-of-first-in-class-myb-mrna-degrader-rem-422-in-patients-with-adenoid-cystic-carcinoma-acc-at-the-american-society-of-clinical-oncology-annual-meeting-2026/2349708

Remix Therapeutics Announces Positive Data from Phase 1/2 ARIA Study of First-in-Class MYB mRNA Degrader, REM-422, in Patients with Adenoid Cystic Carcinoma (ACC) at the American Society of Clinical ...

https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/remix-therapeutics-announces-positive-data-from-phase-12-aria-study-of-first-in-class-myb-mrna-degrader-rem-422-in-patients-with-adenoid-cystic-carcinoma-acc-at-the-american-society-of-clinical-oncology-annual-meeting-2026/2349708
https://www.manilatimes.net/2026/05/17/tmt-newswire/globenewswire/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer/2345706

Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer | The Manila Times

https://www.manilatimes.net/2026/05/17/tmt-newswire/globenewswire/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer/2345706
https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/beyondspring-announces-poster-presentation-at-2026-asco-annual-meeting/2346086

BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting | The Manila Times

https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/beyondspring-announces-poster-presentation-at-2026-asco-annual-meeting/2346086
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/autolus-therapeutics-to-present-clinical-data-update-at-the-american-society-of-clinical-oncology-annual-meeting-2026/2349713

Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026 | The Manila Times

https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/autolus-therapeutics-to-present-clinical-data-update-at-the-american-society-of-clinical-oncology-annual-meeting-2026/2349713
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/asher-biotherapeutics-announces-two-presentations-at-the-asco-2026-annual-meeting-highlighting-clinical-progress-across-its-cd8-targeted-cytokine-pipeline/2349690

Asher Biotherapeutics Announces Two Presentations at the ASCO 2026 Annual Meeting Highlighting Clinical Progress Across Its CD8-Targeted Cytokine Pipeline | The Manila Times

https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/asher-biotherapeutics-announces-two-presentations-at-the-asco-2026-annual-meeting-highlighting-clinical-progress-across-its-cd8-targeted-cytokine-pipeline/2349690